TORONTO, Sept. 13 /CNW/ Abraxis Oncology announced today that it has received Health Canada approval for ABRAXANE(TM) for the treatment of metastatic breast cancer, including previously untreated metastatic disease. ABRAXANE(TM), a unique new cancer therapy, is now commercially available.
